Literature DB >> 20594227

Carbon dioxide-based portography: an alternative to conventional imaging with the use of iodinated contrast medium.

Hitoshi Maruyama1, Hidehiro Okugawa, Hiroyuki Ishibashi, Masanori Takahashi, Satoshi Kobayashi, Hiroaki Yoshizumi, Osamu Yokosuka.   

Abstract

BACKGROUND AND AIM: To clarify the efficacy of carbon dioxide (CO(2)) as a contrast material to evaluate portal vein images by percutaneous transhepatic portography (PTP).
METHODS: Twenty patients (38-76 years; male 13, female 7) with chronic liver diseases were the subjects of this prospective study. Portal venous opacification by PTP was compared between CO(2)-based images and iodinated contrast medium (ICM)-based images by two independent reviewers, according to the three-grade scoring; 0 for none, 1 for weak and 2 for sufficient.
RESULTS: Total scores of extrahepatic portal veins (137 for CO(2), 93 for ICM), collateral vessels (64 for CO(2), 60 for ICM) and intrahepatic portal veins (69 for CO(2), 76 for ICM) were not statistically significant between CO(2)-based and ICM-based images (P = 0.0623). Sufficient opacification of superior mesenteric vein was more frequent on CO(2)-based images (none 0, weak 4, sufficient 16) than ICM-based images (none 19, weak 0, sufficient 1; P < 0.0001). The score was not statistically significant between CO(2)-based and ICM-based images in portal trunk, splenic vein, inferior mesenteric vein and other collateral vessels. Although opacification grade in the intrahepatic left portal vein was not statistically significant between CO(2)-based and ICM-based images (P = 0.1515), weak opacification was significantly frequent on CO(2)-based images (weak 10, sufficient 10) compared to ICM-based images (weak 0, sufficient 20; P = 0.0003) in the intrahepatic right portal vein. Inter-reviewer agreement was excellent between the two reviewers for CO(2)-based images (kappa = 0.913) and ICM-based images (kappa = 0.924).
CONCLUSIONS: Carbon dioxide may be a first-line contrast material for evaluating portal vein images by PTP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20594227     DOI: 10.1111/j.1440-1746.2010.06248.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

Review 1.  Use of carbon dioxide as an intravascular contrast agent: A review of current literature.

Authors:  Fahad Ali; Muhammad Asif Mangi; Hiba Rehman; Edo Kaluski
Journal:  World J Cardiol       Date:  2017-09-26

2.  Targeted puncture of left branch of intrahepatic portal vein in transjugular intrahepatic portosystemic shunt to reduce hepatic encephalopathy.

Authors:  Shi-Hua Luo; Jian-Guo Chu; He Huang; Guo-Rui Zhao; Ke-Chun Yao
Journal:  World J Gastroenterol       Date:  2019-03-07       Impact factor: 5.742

3.  Comparative study of indocyanine green-R15, Child-Pugh score, and model for end-stage liver disease score for prediction of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

Authors:  Zhong Wang; Yi-Fan Wu; Zhen-Dong Yue; Hong-Wei Zhao; Lei Wang; Zhen-Hua Fan; Yu Zhang; Fu-Quan Liu
Journal:  World J Gastroenterol       Date:  2021-02-07       Impact factor: 5.742

4.  Clinical efficacy of transjugular intrahepatic portosystemic shunt created through left or right branches of the portal vein: A meta-analysis.

Authors:  Shaobo Zhai; Qi Cui; Fang Dong; Shiqi Wen; Moubo Si; Quan Chen
Journal:  J Interv Med       Date:  2021-12-23

5.  Influence of different portal vein branches on hepatic encephalopathy during intrahepatic portal shunt via jugular vein.

Authors:  Xin Yao; Sheng He; Meng Wei; Jian-Ping Qin
Journal:  World J Gastroenterol       Date:  2022-08-21       Impact factor: 5.374

6.  Portal flow diversion based on portography is superior than puncture site in the prediction of overt hepatic encephalopathy after TIPS creation.

Authors:  Chongtu Yang; Yang Chen; Chaoyang Wang; Jiacheng Liu; Songjiang Huang; Chen Zhou; Yingliang Wang; Shuguang Ju; Tongqiang Li; Yaowei Bai; Wei Yao; Bin Xiong
Journal:  BMC Gastroenterol       Date:  2022-07-29       Impact factor: 2.847

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.